Seres Therapeutics Inc investor relations material

Seres Therapeutics, Inc. is a microbiome therapeutics platform company that engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate which has completed Phase III clinical trial for the treatment of CDI. It also develops SER-155 and SER-287 which are in Phase Ib clinical trial to reduce incidences of gastrointestinal infections and ulcerative colitis; SER-301 that is in Phase Ib clinical trial to treat metastatic melanoma; and SER-262 to treat Clostridioides difficile infection.